Clinical trials: Schizophrenia Relapse
Schizophrenia
Relapse Prevention Trial Evaluating KarXT Treatment in Schizophrenia
The purpose of the study is to evaluate the relapse prevention of KarXT in the treatment of participants with Schizophrenia
- Trial name
- NCT07686263
- Testing
- Xanomeline/Trospium Chloride
- Where
- 59 sites in United States, Argentina and 7 more
- Volunteers
- 472 people
- Sponsor
- Karuna Therapeutics, Inc., a Bristol Myers Squibb company
Schizophrenia, Psychotic Disorders
A Study of Relapse Prevention and the Effectiveness of Long-acting Injectable Risperidone and Quetiapine Tablets in the Treatment of Patients With Schizophrenia or Schizoaffective Disorder
The purpose of this study is to investigate whether a long-acting injectable formulation of risperidone provides better effectiveness over 2 years, as measured by the time to relapse, compared with quetiapine tablets in a routine…
- Trial name
- NCT00216476
- Testing
- Aripiprazole, Risperidone Long Acting Injectable (LAI), Quetiapine
- Where
- 96 sites in Austria, Bulgaria and 22 more
- Volunteers
- 753 people
- Sponsor
- Janssen-Cilag International NV
Schizophrenia
A Study for Schizophrenia Relapse Prediction
The purpose of this study is to identify if there are self-reported/caregiver reported or objective measures that can predict near-term relapse (within 1 month or at another identified time point before meeting the criteria for…
- Trial name
- NCT03629951
- Testing
- Oral Antipsychotics (OAP)
- Where
- 10 sites in India
- Volunteers
- 333 people
- Sponsor
- Janssen Research & Development, LLC
Tobacco Use Disorder, Schizophrenia
Smoking Abstinence and Lapse Effects in Smokers With Schizophrenia and Controls
This project tests two hypotheses concerning the low smoking cessation rates in smokers with schizophrenia. The first hypothesis is that smokers with schizophrenia experience stronger and more sustained effects of smoking…
- Trial name
- WREN (NCT01214005)
- Testing
- smoking abstinence
- Where
- United States
- Volunteers
- 60 people, healthy volunteers welcome
- Sponsor
- Brown University
Schizophrenia
A Study of Cariprazine in the Prevention of Relapse of Symptoms in Participants With Schizophrenia
The objective of this study is to evaluate the efficacy and safety of cariprazine relative to placebo in the prevention of relapse of symptoms in participants with schizophrenia.
- Trial name
- NCT01412060
- Testing
- Cariprazine
- Where
- 73 sites in United States, India and 3 more
- Volunteers
- 765 people
- Sponsor
- Forest Laboratories
Schizophrenia, Schizoaffective Disorder
Aripiprazole in the Treatment of Acutely Relapsed Patients With Schizophrenia
To evaluate the efficacy, safety and tolerability of aripiprazole in the treatment of acutely relapsed patients with diagnoses of schizophrenia or schizoaffective disorder with risperidone as an active control.
- Trial name
- NCT00283179
- Testing
- Aripiprazole, Risperidone
- Where
- Taiwan
- Volunteers
- 83 people
- Sponsor
- Taiwan Otsuka Pharm. Co., Ltd
Schizophrenia
Voice-Based Biomarkers: A Novel Approach to Monitoring and Predicting Schizophrenia Relapses
Schizophrenia is a serious psychiatric illness affecting approximately 25 million people worldwide. Patients with schizophrenia experience hallucinations, auditory illusions, disordered thinking, movement disorders, cognitive…
- Trial name
- OBSERVSPEECH (NCT06613334)
- Testing
- Blood test: measurement of plasma antipsychotic concentration, Voice interviews and questionnaires carried out via the CALLYOPE application
- Where
- 2 sites in France
- Volunteers
- 200 people
- Sponsor
- Centre Hospitalier St Anne
Schizophrenia
Mozart Relapse Study
To assess the long-term efficacy of oral Ziprasidone in the maintenance treatment of resistant schizophrenic subjects who have benefited from participation in the phase III ziprasidone study A1281039 (MOZART study), to assess the…
- Trial name
- NCT00143351
- Testing
- Ziprasidone
- Where
- 16 sites in Italy
- Volunteers
- 75 people
- Sponsor
- Pfizer's Upjohn has merged with Mylan to form Viatris Inc.
Schizophrenia
Relapse Prevention in First Episode Schizophrenia: a 5 Year Trial
Objective: to evaluate the effectiveness of specialised and sustained intervention with or without parent groups during the initial phase of schizophrenia or related disorders on relapse prevention Methods: A three conditions…
- Trial name
- NCT01936220
- Testing
- Continuity of specialized care, Parent groups combined with Continuity of Specialized care, Discontinuity of care, non specialised care
- Where
- Netherlands
- Volunteers
- 200 people
- Sponsor
- Academisch Medisch Centrum - Universiteit van Amsterdam (AMC-UvA)
Schizoaffective Disorder
Efficacy of Repetitive Transcranial Magnetic Stimulation in the Prevention of Relapse of Schizoaffective
The purpose of this study is to evaluate the efficacy of repetitive transcranial magnetic stimulation in the prevention of relapse of the symptoms of schizoaffective disorder.
- Trial name
- NCT02221635
- Testing
- rTMS + risperidone, Risperidone
- Where
- China
- Volunteers
- 540 people
- Sponsor
- Xijing Hospital
Relapse Rates Related to Website Usage
Web-based Support for People With Schizophrenia and Their Families
This study will assess the feasibility of using the internet and in-home computers to provide advice from health care professionals, social support, and health information to people with schizophrenia and their families.
- Trial name
- NCT00177983
- Testing
- (relapse rate)
- Where
- United States
- Volunteers
- 80 people, healthy volunteers welcome
- Sponsor
- University of Pittsburgh
Schizophrenia
Prevention of Relapse With Injectable Paliperidone Palmitate Versus Oral Antipsychotics
The purpose of this study is to assess the efficacy (how well the drug works; primarily through the time to relapse) of long-acting injectable paliperidone palmitate compared to treatment as usual with orally administered…
- Trial name
- PROSIPAL (NCT01081769)
- Testing
- paliperidone palmitate injection, oral antipsychotics
- Where
- 94 sites in Austria, Belgium and 23 more
- Volunteers
- 769 people
- Sponsor
- Janssen-Cilag International NV
Negative Symptoms of Schizophrenia
Study to Evaluate Efficacy and Safety of Roluperidone in Adult Subjects With Negative Symptoms and Stable Positive Symptoms of Schizophrenia and to Evaluate the Relapse Rate of Roluperidone and Antipsychotic Medications
Evaluate the efficacy, as well as safety and pharmacokinetics, of Roluperidone in improving the negative symptoms of schizophrenia in adult subjects in Phase A of study, followed by Phase B of study to evaluate the relapse rate…
- Trial name
- NCT07565428
- Testing
- Roluperidone, risperidone, aripiprazole
- Where
- 13 sites in United States
- Volunteers
- 380 people
- Sponsor
- Minerva Neurosciences
Schizophrenia, Schizoaffective Disorder
A New Paradigm for Illness Monitoring and Relapse Prevention in Schizophrenia
This study was a 2-arm randomized control trial (RCT) designed to test a multi-modal smartphone data collection system that provided mobile monitoring of schizophrenia to detect early signs of relapse.
- Trial name
- NCT01952041
- Testing
- Device: Smartphone, Treatment as usual
- Where
- United States
- Volunteers
- 149 people
- Sponsor
- Dartmouth-Hitchcock Medical Center
Schizophrenia
Non-interventional Study of Risperidone ISM® in Schizophrenia Patients Hospitalised Due to a Relapse
This is a prospective, non-interventional, multicentre study designed to collect information about the effectiveness, safety and tolerability of Risperidone ISM in patients diagnosed with schizophrenia who are suffering an acute…
- Trial name
- RESHAPE (NCT05480046)
- Testing
- Risperidone ISM
- Where
- 77 sites in Germany, Italy and 3 more
- Volunteers
- 275 people
- Sponsor
- Rovi Pharmaceuticals Laboratories
Schizophrenia
C-Cog in Early Course Schizophrenia Study
The purpose of this study is to examine the role of clinical stability in functional recovery. in first episode schizophrenia.
- Trial name
- NCT05662306
- Testing
- Aripiprazole Lauroxil, Computerized cognitive and functional skills training
- Where
- United States
- Volunteers
- 1 people
- Sponsor
- University of Miami
Psychosis
Predicting Psychotic Relapse Using Speech-Based Early Detection
Psychotic disorders, including schizophrenia and affective psychosis, are severe mental health conditions marked by recurrent episodes that contribute to long-term disability.
- Trial name
- MOTS+ (NCT06978894)
- Where
- 3 sites in Canada
- Volunteers
- 250 people
- Sponsor
- Douglas Mental Health University Institute
Schizophrenia, Schizoaffective Disorder
Preventing Relapse in Schizophrenia: Oral Antipsychotics Compared To Injectables: Evaluating Efficacy
This study is designed to find out whether taking antipsychotic medication once every two weeks by injection compared to taking daily oral medication will help people with schizophrenia maintain better control of their symptoms.
- Trial name
- PROACTIVE (NCT00330863)
- Testing
- Risperidone microspheres, Risperidone, Olanzapine
- Where
- 8 sites in United States
- Volunteers
- 357 people
- Sponsor
- Northwell Health
Dementia-related Psychosis
Relapse Prevention Study of Pimavanserin in Dementia-related Psychosis
The purpose of this study is to evaluate the efficacy of pimavanserin compared to placebo in preventing relapse of psychotic symptoms in subjects with dementia-related psychosis who responded to 12 weeks of open label…
- Trial name
- NCT03325556
- Testing
- Pimavanserin 34 mg, Pimavanserin 20 mg
- Where
- 83 sites in United States, Bulgaria and 11 more
- Volunteers
- 392 people
- Sponsor
- ACADIA Pharmaceuticals Inc.
Schizophrenia
Relapse Prevention Study in Patients With Schizophrenia
The purpose of this study is to determine whether Iloperidone is effective in the prevention of relapse in patients with schizophrenia
- Trial name
- REPRIEVE (NCT01291511)
- Testing
- Iloperidone
- Where
- 63 sites in United States, India and 1 more
- Volunteers
- 635 people
- Sponsor
- Vanda Pharmaceuticals